World's Best Scientists 2026 revealed!

D-Index & Metrics

Discipline name D-Index World Ranking Current World Ranking National Ranking Current National Ranking Publications Citations
Medicine 117 4206 3941 230 222 969 51202

Andreas Engert publications per year

The chart shows the history of publications by Andreas Engert between 1983 and 2023, highlighting the no. of papers published in each year and offering an overview of the publication velocity of this scholar. Andreas Engert published across 41 years, from 1983 to 2023, averaging 25.3 papers a year. Output peaked at 66 publications in 2013. 41 of the 1,039 publications appeared in the last two years.

No. of publications
20 40 60
Bar chart. Horizontal axis: year, 1983 to 2023. Vertical axis: number of publications, 0 to 66. Peak 66 publications in 2013. 1983: 1 publication 1984: 0 publications 1985: 0 publications 1986: 0 publications 1987: 1 publication 1988: 1 publication 1989: 0 publications 1990: 5 publications 1991: 3 publications 1992: 9 publications 1993: 3 publications 1994: 11 publications 1995: 13 publications 1996: 12 publications 1997: 14 publications 1998: 24 publications 1999: 19 publications 2000: 25 publications 2001: 22 publications 2002: 21 publications 2003: 24 publications 2004: 55 publications 2005: 57 publications 2006: 39 publications 2007: 31 publications 2008: 52 publications 2009: 52 publications 2010: 50 publications 2011: 50 publications 2012: 53 publications 2013: 66 publications 2014: 35 publications 2015: 30 publications 2016: 43 publications 2017: 42 publications 2018: 34 publications 2019: 39 publications 2020: 24 publications 2021: 38 publications 2022: 22 publications 2023: 19 publications
1983 2023

1,039 publications in total across all disciplines

View publications per year as a table
Andreas Engert: publications per year, 1983 to 2023
Year Publications
1983 1
1984 0
1985 0
1986 0
1987 1
1988 1
1989 0
1990 5
1991 3
1992 9
1993 3
1994 11
1995 13
1996 12
1997 14
1998 24
1999 19
2000 25
2001 22
2002 21
2003 24
2004 55
2005 57
2006 39
2007 31
2008 52
2009 52
2010 50
2011 50
2012 53
2013 66
2014 35
2015 30
2016 43
2017 42
2018 34
2019 39
2020 24
2021 38
2022 22
2023 19
Total 1,039
Download as CSV

Andreas Engert publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Andreas Engert sits on this spectrum.

No. of scientists
200 400 600 800
Bar chart with 86 bars. Horizontal axis: publications, 101–120 to 1,796+. Vertical axis: number of scientists, 0 to 922. Most scientists, 922, have 341–360 publications. The last bar groups every scientist with 1,796 publications or more. The highlighted bar, 961–980 publications, is where this scientist sits. 101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 610 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101–120 publications 1,796+

This scientist: 969 publications — 93rd percentile

93% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

View publications distribution as a table
Number of Medicine scientists by publication count, Research.com 2026 ranking edition. Based on 20,134 ranked scientists.
Publications Scientists This scientist
101–120 5
121–140 26
141–160 73
161–180 155
181–200 230
201–220 363
221–240 487
241–260 545
261–280 722
281–300 768
301–320 834
321–340 895
341–360 922
361–380 838
381–400 861
401–420 918
421–440 806
441–460 771
461–480 751
481–500 713
501–520 617
521–540 610
541–560 537
561–580 504
581–600 509
601–620 396
621–640 386
641–660 371
661–680 340
681–700 336
701–720 307
721–740 259
741–760 230
761–780 228
781–800 217
801–820 204
821–840 186
841–860 177
861–880 155
881–900 139
901–920 145
921–940 116
941–960 133
961–980 91 969
981–1,000 96
1,001–1,020 77
1,021–1,040 70
1,041–1,060 63
1,061–1,080 77
1,081–1,100 49
1,101–1,120 54
1,121–1,140 49
1,141–1,160 51
1,161–1,180 35
1,181–1,200 39
1,201–1,220 26
1,221–1,240 37
1,241–1,260 36
1,261–1,280 27
1,281–1,300 32
1,301–1,320 28
1,321–1,340 17
1,341–1,360 30
1,361–1,380 28
1,381–1,400 17
1,401–1,420 21
1,421–1,440 15
1,441–1,460 12
1,461–1,480 12
1,481–1,500 18
1,501–1,520 14
1,521–1,540 17
1,541–1,560 15
1,561–1,580 6
1,581–1,600 2
1,601–1,620 12
1,621–1,640 11
1,641–1,660 8
1,661–1,680 5
1,681–1,700 5
1,701–1,720 10
1,721–1,740 12
1,741–1,760 14
1,761–1,780 6
1,781–1,795 5
1,796+ 100
Download as CSV

Andreas Engert D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Andreas Engert sits on this spectrum.

No. of scientists
250 500 750 1,000
Bar chart with 75 bars. Horizontal axis: D-Index, 70–71 to 217+. Vertical axis: number of scientists, 0 to 1,027. Most scientists, 1,027, have 82–83 D-Index. The last bar groups every scientist with 217 D-Index or more. The highlighted bar, 116–117 D-Index, is where this scientist sits. 70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 399 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70–71 D-Index 217+

This scientist: 117 D-Index — 80th percentile

80% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

View D-Index distribution as a table
Number of Medicine scientists by D-index, Research.com 2026 ranking edition. Based on 20,134 ranked scientists.
D-Index Scientists This scientist
70–71 226
72–73 391
74–75 574
76–77 730
78–79 891
80–81 972
82–83 1,027
84–85 1,003
86–87 960
88–89 970
90–91 922
92–93 839
94–95 808
96–97 779
98–99 668
100–101 611
102–103 630
104–105 513
106–107 541
108–109 445
110–111 429
112–113 399
114–115 393
116–117 318 117
118–119 302
120–121 287
122–123 255
124–125 256
126–127 252
128–129 230
130–131 179
132–133 168
134–135 163
136–137 159
138–139 134
140–141 134
142–143 118
144–145 109
146–147 106
148–149 74
150–151 79
152–153 80
154–155 87
156–157 57
158–159 74
160–161 69
162–163 60
164–165 53
166–167 39
168–169 42
170–171 32
172–173 39
174–175 40
176–177 28
178–179 19
180–181 23
182–183 31
184–185 18
186–187 20
188–189 22
190–191 13
192–193 21
194–195 12
196–197 12
198–199 14
200–201 15
202–203 13
204–205 10
206–207 8
208–209 4
210–211 12
212–213 11
214–215 10
216 4
217+ 98
Download as CSV

Overview

Andreas Engert is affiliated with the University of Cologne in Germany and has an extensive research background primarily in medicine, with a focus on pathology and forensic medicine. Their research portfolio includes 219 publications in medicine, with significant contributions to oncology, pulmonary and respiratory medicine, radiology, nuclear medicine and imaging, and neurology. Within these areas, the scientist has concentrated on lymphoma diagnosis and treatment, lung cancer treatments and mutations, cancer immunotherapy and biomarkers, CNS lymphoma diagnosis and treatment, viral-associated cancers and disorders, CAR-T cell therapy research, and immune cell function and interaction.

Engert's frequent coauthors include Peter Borchmann, Michael Fuchs, Paul J. Bröckelmann, Bastian von Tresckow, and Carsten Kobe, indicating a collaborative network with several researchers in hematology and oncology.

The scientist has published predominantly in the following journals: Blood, HemaSphere, British Journal of Haematology, Hematological Oncology, and Journal of Clinical Oncology. The number of publications in each of these venues ranges from six to nine, reflecting a consistent involvement in recognized hematology and oncology outlets.

Notable recent papers authored or coauthored by Engert include:

  • Efficacy of Nivolumab and AVD in Early-Stage Unfavorable Classic Hodgkin Lymphoma (2020, JAMA Oncology)
  • PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trial (2021, The Lancet Oncology)
  • Tumor and microenvironment response but no cytotoxic T-cell activation in classic Hodgkin lymphoma treated with anti-PD1 (2020, Blood)
  • In-depth cell-free DNA sequencing reveals genomic landscape of Hodgkin's lymphoma and facilitates ultrasensitive residual disease detection (2021, Med)
  • Nivolumab and Doxorubicin, Vinblastine, and Dacarbazine in Early-Stage Unfavorable Hodgkin Lymphoma: Final Analysis of the Randomized German Hodgkin Study Group Phase II NIVAHL Trial (2022, Journal of Clinical Oncology)

Best Publications

  • Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma

    Anas Younes;Ajay K. Gopal;Scott E. Smith;Stephen M. Ansell

  • Rituximab (Anti-CD20 Monoclonal Antibody) for the Treatment of Patients With Relapsing or Refractory Aggressive Lymphoma: A Multicenter Phase II Study

    B. Coiffier;C. Haioun;N. Ketterer;A. Engert

  • Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma.

    Andreas Engert;Annette Plütschow;Hans Theodor Eich;Andreas Lohri

  • Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial

    Anas Younes;Armando Santoro;Margaret Shipp;Pier Luigi Zinzani

  • Cytokine-Release Syndrome in Patients With B-Cell Chronic Lymphocytic Leukemia and High Lymphocyte Counts After Treatment With an Anti-CD20 Monoclonal Antibody (Rituximab, IDEC-C2B8)

    U. Winkler;M. Jensen;O. Manzke;H. Schulz

  • Recombinant Human Erythropoietins and Cancer Patients: Updated Meta-Analysis of 57 Studies Including 9353 Patients

    Julia Bohlius;Jayne Wilson;Jerome Seidenfeld;Margaret Piper

  • Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial.

    Philippe Armand;Andreas Engert;Anas Younes;Michelle A Fanale

  • Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial

    Andreas Engert;Heinz Haverkamp;Carsten Kobe;Jana Markova

  • Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials.

    Julia Bohlius;Kurt Schmidlin;Corinne Brillant;Guido Schwarzer

  • Escalated-Dose BEACOPP in the Treatment of Patients With Advanced-Stage Hodgkin's Lymphoma: 10 Years of Follow-Up of the GHSG HD9 Study

    Andreas Engert;Volker Diehl;Jeremy Franklin;Andreas Lohri

  • Involved-Field Radiotherapy Is Equally Effective and Less Toxic Compared With Extended-Field Radiotherapy After Four Cycles of Chemotherapy in Patients With Early-Stage Unfavorable Hodgkin’s Lymphoma: Results of the HD8 Trial of the German Hodgkin’s Lymphoma Study Group

    Andreas Engert;Petra Schiller;Andreas Josting;Richard Herrmann

  • Autologous Stem-Cell Transplantation As First-Line Therapy in Peripheral T-Cell Lymphomas: Results of a Prospective Multicenter Study

    Peter Reimer;Thomas Rüdiger;Eva Geissinger;Florian Weissinger

  • Intensified Chemotherapy and Dose-Reduced Involved-Field Radiotherapy in Patients With Early Unfavorable Hodgkin's Lymphoma: Final Analysis of the German Hodgkin Study Group HD11 Trial

    Hans Theodor Eich;Volker Diehl;Helen Görgen;Thomas Pabst

  • Primary Central Nervous System Lymphoma: Results of a Pilot and Phase II Study of Systemic and Intraventricular Chemotherapy With Deferred Radiotherapy

    Hendrik Pels;Ingo G.H. Schmidt-Wolf;Axel Glasmacher;Holger Schulz

  • Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma : A systematic review and meta-analysis

    Holger Schulz;Julia F. Bohlius;Sven Trelle;Nicole Skoetz

  • Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma

    Robert Chen;Ajay K. Gopal;Scott E. Smith;Stephen M. Ansell

  • Human leukocyte antigen-B-associated transcript 3 is released from tumor cells and engages the NKp30 receptor on natural killer cells.

    Elke Pogge von Strandmann;Venkateswara Rao Simhadri;Bastian von Tresckow;Stephanie Sasse

  • Secondary Amenorrhea After Hodgkin’s Lymphoma Is Influenced by Age at Treatment, Stage of Disease, Chemotherapy Regimen, and the Use of Oral Contraceptives During Therapy: A Report From the German Hodgkin’s Lymphoma Study Group

    Karolin Behringer;Kai Breuer;Thorsten Reineke;Michael May

  • Dose-Intensification in Early Unfavorable Hodgkin's Lymphoma: Final Analysis of the German Hodgkin Study Group HD14 Trial

    Bastian von Tresckow;Annette Plütschow;Michael Fuchs;Beate Klimm

  • PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group.

    Peter Borchmann;Helen Goergen;Carsten Kobe;Andreas Lohri

Frequent Co-Authors

Volker Diehl
Volker Diehl University of Cologne
Michael Hallek
Michael Hallek University of Cologne
Richard Greil
Richard Greil Paracelsus Medical University
Anas Younes
Anas Younes AstraZeneca (United Kingdom)
Kerry J. Savage
Kerry J. Savage University of British Columbia
Harald Stein
Harald Stein Charité - University Medicine Berlin
Holger Schulz
Holger Schulz Universität Hamburg
Andreas Rosenwald
Andreas Rosenwald University of Würzburg
Kari Hemminki
Kari Hemminki Charles University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Considering a career in Medicine extends beyond traditional medical degrees. Many students look for flexible and specialized online programs that align with evolving healthcare needs. For those interested in the intersection of nutrition and health, exploring the best online food science degree programs can open doors to roles in wellness, research, and public health initiatives.

For leadership ambitions in healthcare administration, choosing from a cahme accredited online mha programs list ensures you receive a quality, respected education for management or policy careers.

Nursing professionals seeking career advancement may benefit from online bridge programs such as a rn to bsn online without clinicals. These programs are designed for working nurses who need flexibility and may want to avoid additional clinical requirements.

Lastly, those aiming for advanced practice or leadership roles in nursing might investigate the shortest dnp programs available online, which can accelerate the path to a Doctor of Nursing Practice degree.

Best Scientists Citing Andreas Engert

Trending Scientists